CoChat

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

Open access
Lee, Erinna F., Harris, Tiffany J., Tran, Sharon, Evangelista, Marco, Arulananda, Surein, John, Thomas, Ramnac, Celeste, Hobbs, Chloe, Zhu, Haoran, Gunasingh, Gency, Segal, David, Behren, Andreas, Cebon, Jonathan, Dobrovic, Alexander, Mariadason, John M., Strasser, Andreas, Rohrbeck, Leona, Haass, Nikolas K., Herold, Marco J., Fairlie, W. Douglas · 2019 · Cell Death & Disease
Cited by 185

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Malignant melanoma is one of the most difficult cancers to treat due to its resistance to chemotherapy. Despite recent successes with BRAF inhibitors and immune checkpoint inhibitors, many patients do not respond or become resistant to these drugs. Hence, alternative treatments are still required. Due to the importance of the BCL-2-regulated apoptosis pathway in cancer development and drug resistance, it is of interest to establish which proteins are most important for melanoma cell survival, though the outcomes of previous studies have been conflicting. To conclusively address this question, we tested a panel of established and early passage patient-derived cell lines against several BH3-mimetic drugs designed to target individual or subsets of pro-survival BCL-2 proteins, alone and in combination, in both 2D and 3D cell cultures. None of the drugs demonstrated significant activity as single agents, though combinations targeting MCL-1 plus BCL-XL, and to a lesser extent BCL-2, showed considerable synergistic killing activity that was elicited via both BAX and BAK. Genetic deletion of BFL-1 in cell lines that express it at relatively high levels only had minor impact on BH3-mimetic drug sensitivity, suggesting it is not a critical pro-survival protein in melanoma. Combinations of MCL-1 inhibitors with BRAF inhibitors also caused only minimal additional melanoma cell killing over each drug alone, whilst combinations with the proteasome inhibitor bortezomib was more effective in multiple cell lines. Our data show for the first time that therapies targeting specific combinations of BCL-2 pro-survival proteins, namely MCL-1 plus BCL-XL and MCL-1 plus BCL-2, could have significant benefit for the treatment of melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-019-1568-3

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 185

Metadata

Authors
Lee, E. F., Harris, T. J., Tran, S., Evangelista, M., Arulananda, S., John, T., Ramnac, C., Hobbs, C., Zhu, H., Gunasingh, G., Segal, D., Behren, A., Cebon, J., Dobrovic, A., Mariadason, J. M., Strasser, A., Rohrbeck, L., Haass, N. K., Herold, M. J., & Fairlie, W. D.
Venue
Cell Death & Disease
Published
2019-04-24
Volume
10
Issue
5
Pages
342-342
ISSN
2041-4889 (ISSN-L)
OpenAlex
W2942007182
Cited by
185
References
12
FWCI
8.31
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. https://app.cochat.ai/papers/10.1038/s41419-019-1568-3
The paper
Lee, E. F., Harris, T. J., Tran, S., Evangelista, M., Arulananda, S., John, T., Ramnac, C., Hobbs, C., Zhu, H., Gunasingh, G., Segal, D., Behren, A., Cebon, J., Dobrovic, A., Mariadason, J. M., Strasser, A., Rohrbeck, L., Haass, N. K., Herold, M. J., & Fairlie, W. D. (2019). BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death & Disease. https://doi.org/10.1038/s41419-019-1568-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.